WuXi Biologics has unveiled the WuXia293Stable platform, specifically engineered for the development and manufacturing of challenging-to-express molecules. This innovative platform showcases high titers, human-like glycosylation, and enhanced product quality by addressing truncation issues commonly encountered with complex molecules.
The WuXia293Stable platform boasts stable expression and consistent product quality across extended cell passages, ensuring scalability for both clinical trials and commercial production. By utilizing HEK293 cells, this platform offers a solution for molecules that may face limitations with traditional CHO cell expression systems, where truncation and low titers can be problematic due to specific host cell proteins.
Derived from WuXi Biologics’ proprietary mammalian cell line development platform, WuXia293Stable demonstrates productivity, quality, and stability comparable to the company’s existing WuXia™ platform. It achieves remarkable fed-batch titers of up to 5.0 g/L for monoclonal antibodies while enhancing purity levels, showcasing its versatility for various research and pre-clinical development stages.
WuXi Biologics complements the WuXia293Stable platform with comprehensive services, including cell bank testing and viral clearance validation, providing clients with a streamlined CMC solution. This launch further enhances the capabilities of the WuXia™ platform family, which already includes platforms like WuXiaADCCPlus™ and WuXia RidGS™ to meet diverse customer needs.
Dr. Chris Chen, CEO of WuXi Biologics, emphasized the industry-leading nature of the WuXia293Stable platform, underscoring the company’s commitment to technological innovation and meeting the evolving demands of the biopharmaceutical sector. With a focus on accelerating the delivery of innovative biologics to global patients, WuXi Biologics continues to drive advancements in biotech solutions.
Key Takeaways:
– WuXi Biologics’ WuXia293Stable platform addresses challenges in expressing complex molecules, offering high titers and improved product quality.
– Leveraging HEK293 cells, the platform enables scalable manufacturing and stability across extended cell passages.
– The platform achieves fed-batch titers of up to 5.0 g/L for monoclonal antibodies, showcasing its flexibility for various development stages.
– WuXi Biologics offers a comprehensive suite of services to support the WuXia293Stable platform, enhancing its appeal as a one-stop CMC solution for clients.
Tags: monoclonal antibodies, regulatory
Read more on finance.yahoo.com
You might like to read this–> How Can I Push Recombinant Casein Titers Above 5 g/L in E. coli?